SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report

BACKGROUND: Hyperglycemia is the most common side-effect of phosphatidylinositol 3-kinase (PI3K) inhibitors that are approved for the treatment of some advanced or metastatic breast cancers. This side-effect is likely due to the central role of PI3K in insulin signalling. Here we report the use of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahakian, Nicolas, Cattieuw, Lauranne, Ramillon-Cury, Clotilde, Corroller, Audrey Bégu-Le, Silvestre-Aillaud, Pascale, Béliard, Sophie, Valéro, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290528/
https://www.ncbi.nlm.nih.gov/pubmed/34281618
http://dx.doi.org/10.1186/s40842-021-00125-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290528/
https://www.ncbi.nlm.nih.gov/pubmed/34281618
http://dx.doi.org/10.1186/s40842-021-00125-8

Ejemplares similares